as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti

Company profile
Ticker
RVTY
Exchange
Website
CEO
Prahlad Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Bio-Rad Laboratories • Waters • Illumina • Avantor • Mettler-Toledo International • Bruker • Seer • Prenetics Global Limited • Cue Health ...
Former names
EG&G INC, PERKINELMER INC
SEC CIK
Corporate docs
Subsidiaries
2Cure, LLC • BioLegend CNS, Inc. • BioLegend Ventures, LLC • BioLegend, Inc. • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Immunodiagnostic Systems Inc. • Nexcelom Bioscience Holdings, LLC ...
IRS number
42052042
RVTY stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Results of Operations and Financial Condition
1 Aug 23
SD
Conflict minerals disclosure
31 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Results of Operations and Financial Condition
11 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
28 Apr 23
8-K
Entry into a Material Definitive Agreement
15 Mar 23
ARS
2023 FY
Annual report to shareholders
8 Mar 23
DEFA14A
Additional proxy soliciting materials
8 Mar 23
DEF 14A
Definitive proxy
8 Mar 23
Transcripts
RVTY
Earnings call transcript
2023 Q2
1 Aug 23
RVTY
Earnings call transcript
2023 Q1
11 May 23
RVTY
Earnings call transcript
2022 Q3
8 Nov 22
RVTY
Earnings call transcript
2022 Q2
5 Aug 22
RVTY
Earnings call transcript
2022 Q1
4 May 22
RVTY
Earnings call transcript
2021 Q4
2 Feb 22
RVTY
Earnings call transcript
2021 Q3
3 Nov 21
RVTY
Earnings call transcript
2021 Q2
29 Jul 21
RVTY
Earnings call transcript
2021 Q1
5 May 21
RVTY
Earnings call transcript
2020 Q4
3 Feb 21
Latest ownership filings
11-K/A
Annual report of employee stock purchases (amended)
21 Jul 23
11-K
Annual report of employee stock purchases
28 Jun 23
4
Anita Gonzales
16 Jun 23
3
Anita Gonzales
16 Jun 23
SC 13G/A
T. Rowe Price Investment Management, Inc.
12 Jun 23
4
Samuel R. Chapin
17 May 23
4
ALEXIS P MICHAS
17 May 23
4
Frank Witney
17 May 23
4
Sylvie Gregoire
17 May 23
4
Peter Barrett
17 May 23
Financial summary
Quarter (USD) | Jul 23 | Apr 23 | Jan 23 | Oct 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.33 bn | 1.33 bn | 1.33 bn | 1.33 bn | 1.33 bn | 1.33 bn |
Cash burn (monthly) | 311.75 mm | (no burn) | (no burn) | (no burn) | 45.11 mm | (no burn) |
Cash used (since last report) | 854.16 mm | n/a | n/a | n/a | 123.59 mm | n/a |
Cash remaining | 479.16 mm | n/a | n/a | n/a | 1.21 bn | n/a |
Runway (months of cash) | 1.5 | n/a | n/a | n/a | 26.8 | n/a |
Institutional ownership, Q2 2023
82.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 504 |
Opened positions | 43 |
Closed positions | 82 |
Increased positions | 148 |
Reduced positions | 204 |
13F shares | Current |
---|---|
Total value | 12.11 tn |
Total shares | 102.32 mm |
Total puts | 50.60 k |
Total calls | 84.80 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.51 mm | $1.72 tn |
T. Rowe Price Investment Management | 12.72 mm | $1.51 tn |
Select Equity | 11.36 mm | $1.35 tn |
BLK Blackrock | 8.48 mm | $1.01 tn |
Capital Research Global Investors | 8.29 mm | $984.85 bn |
STT State Street | 5.28 mm | $627.80 bn |
JHG Janus Henderson | 4.65 mm | $551.92 bn |
Geode Capital Management | 2.64 mm | $312.56 bn |
Pictet Asset Management | 2.13 mm | $253.42 bn |
MS Morgan Stanley | 1.61 mm | $191.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jun 23 | Anita Gonzales | Common Stock | Grant | Acquire A | No | No | 0 | 329 | 0.00 | 3,611 |
15 Jun 23 | Anita Gonzales | NQ Stock Option Common Stock | Grant | Acquire A | No | No | 116.36 | 947 | 110.19 k | 947 |
15 May 23 | Chapin Samuel R. | Common Stock | Grant | Acquire A | No | No | 0 | 955 | 0.00 | 15,789 |
15 May 23 | Chapin Samuel R. | Common Stock | Grant | Acquire A | No | No | 0 | 783 | 0.00 | 14,834 |
15 May 23 | Michas Alexis P | Common Stock | Grant | Acquire A | No | No | 0 | 1,372 | 0.00 | 60,584 |
15 May 23 | Michas Alexis P | Common Stock | Grant | Acquire A | No | No | 0 | 1,061 | 0.00 | 59,212 |
15 May 23 | Witney Frank | Common Stock | Grant | Acquire A | No | No | 0 | 955 | 0.00 | 16,467 |
15 May 23 | Witney Frank | Common Stock | Grant | Acquire A | No | No | 0 | 783 | 0.00 | 15,512 |
15 May 23 | Gregoire Sylvie | Common Stock | Grant | Acquire A | No | No | 0 | 955 | 0.00 | 20,482 |
15 May 23 | Gregoire Sylvie | Common Stock | Grant | Acquire A | No | No | 0 | 783 | 0.00 | 19,527 |
Press releases
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
5 Sep 23
Revvity to Present at Upcoming September Investor Conferences
23 Aug 23
Revvity Announces Financial Results for the Second Quarter of 2023
1 Aug 23
Revvity Board Declares Quarterly Dividend
21 Jul 23
Revvity to Hold Earnings Call on Tuesday, August 1, 2023
12 Jul 23